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Abstract
In carcinoma tissues, genetic and metabolic changes not only occur at the tumor cell level, but also in the sur-
rounding stroma. This carcinoma-reactive stromal tissue is heterogeneous and consists e.g. of non-epithelial cells
such as fibroblasts or fibrocytes, inflammatory cells and vasculature-related cells, which promote carcinoma growth
and progression of carcinomas. Nevertheless, there is just little knowledge about the proteomic changes from nor-
mal connective tissue to tumor stroma. In the present study, we acquired and analysed specific protein patterns of
small stromal sections surrounding head and neck cell complexes in comparison to normal subepithelial connec-
tive tissue. To gain defined stromal areas we used laser-based tissue microdissection. Because these stromal areas
are limited in size we established the highly sensitive ‘tissue on chip based mass spectrometry’ (toc-MS). Therefore,
the dissected areas were directly transferred to chromatographic arrays and the proteomic profiles were subse-
quently analysed with mass spectrometry. At least 100 cells were needed for an adequate spectrum. The locating
of differentially expressed proteins enables a precise separation of normal and tumor stroma. The newly described
toc-MS technology allows an initial insight into proteomic differences between small numbers of exactly defined
cells from normal and tumor stroma.
Findings
Carcinoma tissue does not only consist of tumor cells
but also of fibroblasts, endothelial cells or vascular
structures, and inflammatory cells forming the so-called
desmoplastic stroma reaction or supportive tumor
stroma. Many steps in carcinoma development e.g. pro-
liferation, angiogenesis, invasion and metastasis are pro-
moted by microenvironmental factors produced by these
stromal cells. It is well known that the reciprocal inter-
actions between tumor and stroma cells, i.e., cancer
associated fibroblasts (CAF), tumor endothelial cells
(TEC) and tumor associated macrophages (TAM) result
in tumor progression. The close vicinity of CAFs to the
cancer cells enhance tumor growth by secreting growth
factors like transforming growth factor beta (TGF beta),
matrix degrading enzymes like matrix metalloprotei-
nases (MMP) and angiogenic factors such as vascular
endothelial growth factors (VEGF) [1]. The investigation
of those microenvironmental factors at the proteomic
level requires a technical workflow that enables the iso-
lation of small defined areas of stroma on the one hand
and a sufficient high sensitivity to analyse these small
amounts of cells on the other hand. One part of this
attempt is the laser-based tissue microdissection [2].
Hereby, small areas of interest can be easily separated
from the remaining tissue and further analyzed with
genomic or proteomic approaches. The second prerequi-
site for the proteomic analysis of stromal cells is a
highly sensitive detection technique. Gel-based techni-
ques do not meet this requirement but mass spectrome-
try by MALDI (matrix assisted laser desorption and
ionization) seems to be a better choice as shown in sev-
eral studies using microdissected tissue [2,3]. Using affi-
nity chromatographic surfaces SELDI (surface enhanced
laser desorption and ionization) offers the highest sensi-
tivity - but with low resolution - and is a commonly
used tool to investigate differentially expressed proteins
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in body fluids, cells and tissue [4-9]. In general, SELDI is
useful to compare crude protein lysates with a high sen-
sitivity; MALDI, in contrast, displays a higher resolution
which is useful for the identification of proteins. So far,
after microdissection about 3000-5000 cells are needed
to receive an adequate proteomic profile. Nevertheless,
it is tedious to reach even this cell number from small
stromal areas within a tumor. Therefore, the purpose of
this study was to develop and refine a proteomic techni-
que which is sensitive enough to analyse as few as a
hundred microdissected cells.
Microdissection of stroma from normal and tumor tissue
All head and neck tumor samples (n = 14) and normal
controls (n = 14) were obtained after surgical resection
at the ENT (Ear, Nose, Throat) Department of the Uni-
versity Hospital Jena; they had been collected fresh,
snap frozen in liquid nitrogen, and were stored at -80°C.
Tumor specimen were categorized to the WHO classifi-
cation criteria [10]. Ethical approval was obtained from
the local Research Ethic Committee.
From these samples 12 μm cryostat sections were pre-
pared. One section was stained with hematoxylin-eosin
(HE) and examined microscopically in order to detect
tissue areas of interest for microdissection (see [11]). A
corresponding unstained tissue section was mounted on
a microscope slide coated with a 1.35 μm membrane
(polyethylene naphtalate (PEN) Zeiss/Palm, Bernried,
Germany). Tissue areas from normal and tumor stroma
(approx. size 300 × 300 μm) containing approximately
100 to 500 cells were cut out and moved by a laser
microdissection and pressure catapulting microscope
(LMPC; Zeiss/Palm, Bernried, Germany) or a fine needle
directly on ProteinChip arrays (Fig. 1). For catapulting, a
microplasma is induced under the dissected tissue area.
This plasma lifts the piece of tissue to a reaction cup or
to a ChipArray fixed by a special mount, each. For regu-
lar formed tissue pieces with more than 100 cells we
found that it is more secure to attach the dissected area
to a fine needle and deposit it elsewhere under micro-
scopically control.
Applying microdissected tissue onto ProteinChip arrays
and mass spectrometric analysis
A Q10 ProteinChip array (strong anion exchanger;
BioRad) was activated (see [11]) and wetted with 0.5 μl
lysis buffer (100 mM Na-phosphate (pH 7.5), 5 mM
EDTA, 2 mM MgCl2, 3 mM 2-b-mercaptoethanol, 0.1%
CHAPS, 500 μM leupeptine, and 0.1 mM PMSF). Under
a stereo microscope (Stemi 2000c, Zeiss) the tissue sec-
tion was placed on the spot of the ProteinChip array.
Tissue lysis on spot was performed for 1.5 h at 4°C in a
humidity chamber. After lysis and incubation the spots
were washed three times with 5 μl of a washing/binding
buffer (100 mM Tris-buffer, pH 8.5 with 0.02% Triton
X-100) and rinsed 2 times with water. 2 × 0.5 μl
sinapinic acid (saturated solution in 0.5% TFA/50% acet-
onitrile) was applied as matrix on the dried spots. The
matrix which co-crystallizes with proteins absorbs the
laser energy and transfers part of its charge to the pro-
teins. Mass analysis was performed in a ProteinChip
Reader (PCS 4000, Ciphergen Biosystems Inc, Fremont,
CA) with a manual data collection protocol.
Because cells were microdissected, placed and lysed
directly on the spot of the ProteinChip array under con-
trol of a stereo microscope, we named this technique
‘tissue on chip based mass spectrometry’ (toc-MS).
Areas of different size and cell number were tested. At
least 100 cells were needed for an adequate spectrum.
For the analysis of the normal and tumor samples 300
cells were dissected for more robust results. Compared
to the SELDI standard procedure the sensitivity is
increased at least tenfold and, because no protein lysis
and extraction is needed, time of analysis is shorter by
half. In contrast to MALDI imaging, which allows to
analyse spatial resolved protein spectra over tissue sec-
tions and other mass spectrometry techniques, the
SELDI characteristic affinity chromatograhic chip sur-
faces allow a more quantitative analysis of proteins.
Bioinformatic analysis of mass spectrometry data
The resulting protein profiles between 2 kDa to 20 kDa
(low range) and 20 kDa to 200 kDa (high range) were
subjected to CiphergenExpress™ Client 3.0 software (CE)
and a cluster and rule-based data mining algorithm
(XLminer 3.0, BioControl Jena GmbH). The CE software
was used for the processing of raw spectra and the cal-
culation of P-values and cluster plots. In the low range
we found 8 peaks with a P-value lower 0.05. In the high
range 5 peaks with this characteristic could be found.
The two most significant proteins for the low and high
range are displayed in box plots in Figure 2.
The 7,477 Da peak is significantly higher expressed (P
= 0.0003) in tumor stroma, while the 80,044 Da peak (P
= 0.0009) is reduced in tumor stroma. An initial data
base search according molecular size offered for the
7,477 Da mass the beta defensin 119 (UniProtKB/Swiss-
Prot Q8N690 Chain: 22-84: 7493 Da). Human beta-
defensines (HBD) are cationic, antimicrobial peptides
produced by epithelial cells and show altered inconsis-
tent expression in cancers [12,13]. Analyses of their
expression in tumor stroma are not published yet. For
the fibroblast growth factor 23 only a role in phosphate
homeostasis and related disorders is known [14]. The
protein with a molecular mass of 80,044 Da is equiva-
lent in size to the unphosphorylated ski oncogene (Uni-
ProtKB/Swiss-Prot P12755, 80,005 Da) which was
discovered as oncogene by its ability to transform
chicken embryo fibroblasts upon overexpression. But in
newer studies also anti-oncogenic activities are discussed
(for review see [15]).
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Figure 1 Principle of tissue on chip based mass spectrometry (toc-MS): (A) Head and neck cancer (HNC) tissue sections were stained
H&E to obtain an overview of the tissue architecture. (B) Exemplary cutting lines of laser microdissection. (C) Stroma areas with about 100
square μm were cut out using the laser microdissection and transferred on a ProteinChip array (D). The same procedure was performed with
normal connective tissue (not to scale).
Figure 2 A: Example of a peak (7.48 kDa) significantly higher expressed in tumor (Tu) stroma compared to normal (N) stroma. Intensity
is plotted on X-Axis. b: Example of a peak (89.04 kDa) significantly lower expressed in tumor (Tu) stroma compared to normal (N) stroma.
Intensity is plotted on X-Axis
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The subsequent modified fuzzy c-means data analysis
algorithm underlying the XLminer software [5] consists
of three steps in particular allowing adequate analysis of
small sample groups. The clustering step, the rule
extraction and rating step, and the rule-base construc-
tion step finally result in a heat-map and in values for
sensitivity and specificity separating both groups. The
analysis of all tumor and normal samples with XLminer
resulted in a sensitivity of up to 92.8% and a specificity
of 100% (Fig. 3).
In conclusion, we applied toc-MS successfully to ana-
lyse a few hundred stromal cells quantitatively and to
differentiate between those stromal areas near to tumor
and to normal epithelium. An exact identification of
these proteins with tryptic digestion and tandem MS is
in progress. Ongoing research focuses on down-scaling
the procedure to a higher sensitivity.
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